TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma
- PMID: 25475555
- DOI: 10.1016/j.canlet.2014.11.056
TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma
Abstract
In neuroblastoma, MYCN amplification is associated with a worse prognosis and is a criterion used in the clinic to provide intensive treatments to children even with localized disease. In correlation with MYCN amplification, upregulation of TWIST1, a transcription factor playing a crucial role in inhibition of apoptosis and differentiation, was previously reported. Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification. In silico analyses reveal the presence of several MYC regulatory motifs (E-Boxes and INR) within the TWIST1 promoter. Using gel shift assay and reporter activity assays, we demonstrate that both N-Myc and c-Myc proteins can bind and activate the TWIST1 promoter. Therefore, we propose TWIST1 as a direct MYC transcriptional target.
Keywords: MYC; MYCN; TWIST1; Transcriptional regulation neuroblastoma.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.Genome Biol. 2008 Oct 13;9(10):R150. doi: 10.1186/gb-2008-9-10-r150. Genome Biol. 2008. PMID: 18851746 Free PMC article.
-
Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.Int J Cancer. 2013 Feb 1;132(3):E106-15. doi: 10.1002/ijc.27787. Epub 2012 Sep 26. Int J Cancer. 2013. PMID: 22907398
-
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19. FASEB J. 2011. PMID: 21856782 Free PMC article.
-
The MYCN oncoprotein as a drug development target.Cancer Lett. 2003 Jul 18;197(1-2):125-30. doi: 10.1016/s0304-3835(03)00096-x. Cancer Lett. 2003. PMID: 12880971 Review.
-
The MYCN oncogene and differentiation in neuroblastoma.Semin Cancer Biol. 2011 Oct;21(4):256-66. doi: 10.1016/j.semcancer.2011.08.001. Epub 2011 Aug 9. Semin Cancer Biol. 2011. PMID: 21849159 Review.
Cited by
-
Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.Pediatr Blood Cancer. 2018 Jan;65(1):10.1002/pbc.26721. doi: 10.1002/pbc.26721. Epub 2017 Sep 5. Pediatr Blood Cancer. 2018. PMID: 28873262 Free PMC article.
-
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.Sci Adv. 2022 Jul 15;8(28):eabn1382. doi: 10.1126/sciadv.abn1382. Epub 2022 Jul 13. Sci Adv. 2022. PMID: 35857500 Free PMC article.
-
EZH2-TROAP Pathway Promotes Prostate Cancer Progression Via TWIST Signals.Front Oncol. 2021 Feb 22;10:592239. doi: 10.3389/fonc.2020.592239. eCollection 2020. Front Oncol. 2021. PMID: 33692939 Free PMC article.
-
Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities.MedComm (2020). 2022 May 18;3(2):e144. doi: 10.1002/mco2.144. eCollection 2022 Jun. MedComm (2020). 2022. PMID: 35601657 Free PMC article. Review.
-
A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.Cancers (Basel). 2021 Nov 3;13(21):5528. doi: 10.3390/cancers13215528. Cancers (Basel). 2021. PMID: 34771690 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical